Please login to the form below

Not currently logged in
Email:
Password:

Thalidomide research breakthrough

Researchers at the University of Aberdeen have discovered why limb defects occur in babies born to mothers who have taken thalidomide

Researchers at the University of Aberdeen, in Scotland, have discovered why limb defects occur in babies born to mothers who have taken thalidomide.

Dr Neil Vargesson, who led the research, said: "We have put to rest a 50-year puzzle, in finally deducing how thalidomide triggers limb defects and why it appears to target limbs preferentially." The paper published today in Proceedings of the National Academy of Sciences reveals that the drug prevents the growth of new blood vessels. 

In the 1950s thalidomide was prescribed to treat morning sickness and was taken during the stage of pregnancy when limbs are developed in the embryo. It is thought to have caused about 10,000 babies to be born with deformities. 

The drug has multiple actions, some of which are of great medical value - such as in the treatment of leprosy. Although the risks are now known, in South America and Africa some children with limb defects are born to mothers who have been treated with thalidomide.

The research reveals that only one component causes birth abnormalities and this could lead to new therapies that retain the benefits without the risk. Thalidomide can stop tumours growing larger and is used to treat some cancers. Further therapeutic indications could be investigated if the risks to the unborn child are eliminated.

12th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics